[go: up one dir, main page]

MX2020008258A - Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. - Google Patents

Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.

Info

Publication number
MX2020008258A
MX2020008258A MX2020008258A MX2020008258A MX2020008258A MX 2020008258 A MX2020008258 A MX 2020008258A MX 2020008258 A MX2020008258 A MX 2020008258A MX 2020008258 A MX2020008258 A MX 2020008258A MX 2020008258 A MX2020008258 A MX 2020008258A
Authority
MX
Mexico
Prior art keywords
pediatric
treatment methods
niraparib
niraparib formulations
formulations
Prior art date
Application number
MX2020008258A
Other languages
English (en)
Inventor
Clare Medendorp
John Chaber
Simon Mcgurk
David Lust
Kevin Johnston
Duantel Verwijs
Aaron Nelson
Melanie Ronsheim
Steve Ruddy
Katie Poutsiaka
Hoorn Danny Van
Aileen Dowling
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of MX2020008258A publication Critical patent/MX2020008258A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

La presente invención se refiere a métodos para tratar el cáncer en sujetos pediátricos que comprenden la administración del compuesto de niraparib en una forma de dosificación oral adecuada y, opcionalmente, en combinación con un segundo agente terapéutico, tal como un inhibidor de PD-1.
MX2020008258A 2018-02-05 2019-02-05 Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. MX2020008258A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862626644P 2018-02-05 2018-02-05
US201862626646P 2018-02-05 2018-02-05
PCT/US2019/016648 WO2019152989A1 (en) 2018-02-05 2019-02-05 Pediatric niraparib formulations and pediatric treatment methods

Publications (1)

Publication Number Publication Date
MX2020008258A true MX2020008258A (es) 2020-11-13

Family

ID=65494567

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008258A MX2020008258A (es) 2018-02-05 2019-02-05 Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.

Country Status (14)

Country Link
US (1) US20210030735A1 (es)
EP (1) EP3749352A1 (es)
JP (1) JP2021513524A (es)
KR (1) KR20200118117A (es)
CN (1) CN111918667A (es)
AU (1) AU2019215450A1 (es)
BR (1) BR112020015909A2 (es)
CA (1) CA3090479A1 (es)
IL (1) IL276494A (es)
MX (1) MX2020008258A (es)
RU (1) RU2020129236A (es)
SG (1) SG11202007420PA (es)
TW (1) TW201944999A (es)
WO (1) WO2019152989A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018183354A1 (en) 2017-03-27 2018-10-04 Tesaro, Inc. Niraparib compositions
ES2926255T3 (es) 2017-04-24 2022-10-24 Tesaro Inc Métodos de fabricación de niraparib
CN110831580A (zh) 2017-05-09 2020-02-21 特沙诺有限公司 用于治疗癌症的组合疗法
AU2018270112A1 (en) 2017-05-18 2019-12-12 Tesaro, Inc. Combination therapies for treating cancer
JP7269227B2 (ja) 2017-09-26 2023-05-08 テサロ， インコーポレイテッド ニラパリブ処方物
CA3076515A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. Combination therapies for treating cancer
CN111182923A (zh) 2017-10-06 2020-05-19 特沙诺有限公司 组合疗法及其用途
KR20200096788A (ko) * 2017-12-06 2020-08-13 지앙수 헨그루이 메디슨 컴퍼니 리미티드 화학치료법-내성 난소암 또는 유방암 치료에서 parp 억제제의 용도
TWI852940B (zh) * 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
CA3163564A1 (en) * 2019-12-31 2021-07-08 Xiaokun SHEN A drug combination for treating tumors and its application
EP4153145A4 (en) * 2020-05-18 2024-05-29 Board of Regents, The University of Texas System GRANULES FOR 3D PRINTING TECHNOLOGY
KR20240093836A (ko) * 2021-11-10 2024-06-24 크리티테크, 인크. 니라파립 입자 및 이의 용도
AU2022422129B2 (en) * 2021-12-23 2025-10-23 Boston Scientific Medical Device Limited Chemoembolic compositions and methods of treatment using them
CN119156216A (zh) * 2022-02-15 2024-12-17 特沙诺有限公司 尼拉帕尼用于治疗脑癌的用途
WO2024238587A1 (en) * 2023-05-17 2024-11-21 Tesaro, Inc. Novel use of an inhibior of the a poly-adp ribose polymerase (parp) in the treatment of cancer
WO2025085707A1 (en) * 2023-10-19 2025-04-24 Tesaro, Inc. Methods of treating cancer with anti-pd-1 agents

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606337D0 (en) 1996-03-26 1996-05-29 Freeman Reginald E Rheometer
US7997103B2 (en) * 2002-12-10 2011-08-16 Lg Electronics Inc. Tub having structurally strengthened rear wall and washing machine with the same therein
US20090275619A1 (en) 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
WO2009087381A1 (en) 2008-01-08 2009-07-16 Merck Sharp & Dohme Ltd Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
MX362039B (es) * 2010-11-04 2019-01-07 Boehringer Ingelheim Int Anticuerpos anti-il-23.
US20150283083A1 (en) * 2012-11-19 2015-10-08 Azanta A/S Dispersible Tablet
KR20150090921A (ko) * 2012-12-04 2015-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 유방암 치료에서 에리불린의 용도
US9738915B2 (en) 2012-12-07 2017-08-22 Merck Sharp & Dohme Corp. Biocatalytic transamination process
WO2014088983A1 (en) 2012-12-07 2014-06-12 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
HUE053069T2 (hu) 2013-05-02 2021-06-28 Anaptysbio Inc Programozott halál-1 (PD-1) ellen irányuló ellenanyagok
EP3063129B1 (en) * 2013-10-25 2019-04-17 Life Technologies Corporation Novel compounds for use in pcr systems and applications thereof
JP6648040B2 (ja) * 2014-05-28 2020-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用
CN107750167B (zh) * 2015-04-20 2021-05-25 效应物治疗公司 用于治疗癌症和感染的免疫检查点调节剂的抑制剂
KR20180029079A (ko) * 2015-07-31 2018-03-19 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 암에 대한 면역 체크포인트 억제제와의 조합 요법에서의 조혈 줄기 세포
EP3377068B1 (en) * 2015-11-20 2025-03-26 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
CA2916970A1 (en) * 2016-01-08 2017-07-08 Pharmascience Inc. A smac mimetic compound for use in the treatment of proliferative diseases
US20190133980A1 (en) * 2016-06-02 2019-05-09 Yale University Compositions and methods for targeting and treating homologous recombination-deficient tumors
CA3029671C (en) * 2016-06-29 2023-08-15 Tesaro, Inc. Methods of treating ovarian cancer
TW201842908A (zh) 2017-03-27 2018-12-16 美商提薩羅有限公司 尼拉帕尼(niraparib)調配物
WO2018183354A1 (en) 2017-03-27 2018-10-04 Tesaro, Inc. Niraparib compositions
AU2018270112A1 (en) * 2017-05-18 2019-12-12 Tesaro, Inc. Combination therapies for treating cancer

Also Published As

Publication number Publication date
TW201944999A (zh) 2019-12-01
KR20200118117A (ko) 2020-10-14
WO2019152989A1 (en) 2019-08-08
CN111918667A (zh) 2020-11-10
BR112020015909A2 (pt) 2020-12-15
AU2019215450A1 (en) 2020-08-27
RU2020129236A (ru) 2022-03-09
IL276494A (en) 2020-09-30
EP3749352A1 (en) 2020-12-16
JP2021513524A (ja) 2021-05-27
SG11202007420PA (en) 2020-09-29
US20210030735A1 (en) 2021-02-04
CA3090479A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
WO2016133903A3 (en) Combination therapy for cancer treatment
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
ZA202000028B (en) Use of vibegron to treat overactive bladder
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
WO2015035410A8 (en) Cancer therapy
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
MX2021001084A (es) Terapia de combinacion para el tratamiento del cancer.
MX2019011749A (es) Reduccion de la expresion de beta-catenina para potenciar la inmunoterapia.